- Home
- CCIF vs KRRO Comparison
CCIF vs KRRO Comparison
Compare CCIF & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- KRRO
- Stock Information
- Founded
- CCIF 2011
- KRRO 2014
- Country
- CCIF United States
- KRRO United States
- Employees
- CCIF N/A
- KRRO N/A
- Industry
- CCIF Finance/Investors Services
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- KRRO Health Care
- Exchange
- CCIF Nasdaq
- KRRO Nasdaq
- Market Cap
- CCIF 121.6M
- KRRO 125.4M
- IPO Year
- CCIF N/A
- KRRO 2019
- Fundamental
- Price
- CCIF $5.65
- KRRO $16.26
- Analyst Decision
- CCIF
- KRRO Strong Buy
- Analyst Count
- CCIF 0
- KRRO 7
- Target Price
- CCIF N/A
- KRRO $85.67
- AVG Volume (30 Days)
- CCIF 76.9K
- KRRO 115.7K
- Earning Date
- CCIF 01-01-0001
- KRRO 08-12-2025
- Dividend Yield
- CCIF 25.90%
- KRRO N/A
- EPS Growth
- CCIF N/A
- KRRO N/A
- EPS
- CCIF N/A
- KRRO N/A
- Revenue
- CCIF N/A
- KRRO $4,821,000.00
- Revenue This Year
- CCIF N/A
- KRRO $65.08
- Revenue Next Year
- CCIF N/A
- KRRO N/A
- P/E Ratio
- CCIF N/A
- KRRO N/A
- Revenue Growth
- CCIF N/A
- KRRO N/A
- 52 Week Low
- CCIF $7.43
- KRRO $10.29
- 52 Week High
- CCIF $10.16
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- CCIF 27.82
- KRRO 60.76
- Support Level
- CCIF $5.51
- KRRO $14.75
- Resistance Level
- CCIF $5.76
- KRRO $17.82
- Average True Range (ATR)
- CCIF 0.16
- KRRO 1.37
- MACD
- CCIF -0.08
- KRRO 0.27
- Stochastic Oscillator
- CCIF 12.96
- KRRO 70.59
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.